{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:45Z","timestamp":1791983685914,"version":"4.4.0"},"reference-count":15,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100008953","name":"Prometheus","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100008953","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0522-3","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T15:04:16Z","timestamp":1550502256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":145,"title":["Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8953","authenticated-orcid":false,"given":"Elizabeth I.","family":"Buchbinder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice P.","family":"Dutcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan D.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shernan G.","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald P.","family":"Miletello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayer N.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph I.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Richart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott S.","family":"Tykodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W.","family":"Silk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"522_CR1","doi-asserted-by":"crossref","unstructured":"Atkins, M.B., et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 1999. 17(7): p. 2105\u20132116.","DOI":"10.1200\/JCO.1999.17.7.2105"},{"issue":"3","key":"522_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688\u201396.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"522_CR3","first-page":"P319","volume":"5","author":"J Clark","year":"2017","unstructured":"Clark J, Curti BD, Davis E, Kaufman H, Amin A, Alva A, Logan T, Hauke R, Miletello G, Vaishampayan U, Johnson D, White R, Wiernik P, Dutcher J. Long-term disease-free survival (DFS) of metastatic melanoma (mM) and renal cell cancer (mRCC) patients following high-dose interleukin-s (HD IL2). JITC. 2017;5(Suppl 2):P319.","journal-title":"JITC"},{"issue":"4","key":"522_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","volume":"83","author":"US Kammula","year":"1998","unstructured":"Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83(4):797\u2013805.","journal-title":"Cancer"},{"issue":"8","key":"522_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"21","key":"522_CR6","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"},{"issue":"10","key":"522_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"522_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"9948","key":"522_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317.","journal-title":"Lancet"},{"issue":"19","key":"522_CR10","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"6","key":"522_CR11","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1172\/JCI67008","volume":"123","author":"EE West","year":"2013","unstructured":"West EE, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013;123(6):2604\u201315.","journal-title":"J Clin Invest"},{"issue":"7","key":"522_CR12","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","volume":"18","author":"PA Prieto","year":"2012","unstructured":"Prieto PA, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039\u201347.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"522_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber JS, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943\u201355.","journal-title":"Lancet Oncol"},{"issue":"1","key":"522_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-018-0387-x","volume":"6","author":"JI Clark","year":"2018","unstructured":"Clark JI, et al. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. J Immunother Cancer. 2018;6(1):76.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"522_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/0092-8674(93)90152-G","volume":"73","author":"T Taniguchi","year":"1993","unstructured":"Taniguchi T, Minami Y. The IL-2\/IL-2 receptor system: a current overview. Cell. 1993;73(1):5\u20138.","journal-title":"Cell"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:51Z","timestamp":1601056011000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0522-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review boards of the sites enrolling subjects and all patients provided written, informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EB receives clinical trial support from BMS and Merck, JD receives consulting income from Prometheus, BMS, Tracon, Iovance, Eisai, Merck, and Amgen, SH receives consulting income from Incyte, AS receives clinical trial support from BMS and Merck and receives consulting income from Merck. JC receives consulting income from BMS and Merck. ST receives clinical trial support from Peloton Therapeutics, Merck, Nektar Therapeutics, Calithera Biosciences, Jounce Therapeutics Pfizer, Genentech, ARGOS Therapeutics and BMS, he also receives consulting honoraria from Calithera Biosciences, Prometheus Laboratories and Bristol-Myers Squibb. GD, BC, SP, SH, GM, MF, RG, JC, JR, CL ST, AS and DM all receive institutional research funding from Prometheus. DM receives consulting honoraria from BMS, Pfizer, Merck, Novartis, Eisai, Exelixis, Array, Genentech and Jounce.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"49"}}